Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Dose-Dense Neoadjuvant Chemotherapy Plus Herceptin in HER2+ Breast Cancer
NCT00270894Phase 2Completed
- Sponsor
- Accelerated Community Oncology Research Network
- Start
- Nov 2005
- Primary completion
- Aug 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Accelerated Community Oncology Research Network. Primary endpoints: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule at 20 weeks and Frequency of Grade 3 or 4 Hematologic and Nonhematologic Toxicities at 25 weeks. Started Nov 2005; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00270894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270894.